View in EDS

291O DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC).

Saved in:
Bibliographic Details
Title: 291O DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC).
Authors: Harbeck, N.1 (AUTHOR), Modi, S.2 (AUTHOR), Pusztai, L.3 (AUTHOR), Ohno, S.4 (AUTHOR), Wu, J.5 (AUTHOR), Kim, S.B.6 (AUTHOR), Fabi, A.7 (AUTHOR), Cao, X.8 (AUTHOR), Joseph, R.9 (AUTHOR), Li, R.10 (AUTHOR), Zurawski, B.11 (AUTHOR), Escrivá-de-Romaní, S.12 (AUTHOR), Chen, S.C.13 (AUTHOR), Kelly, C.14 (AUTHOR), Curigliano, G.15 (AUTHOR), Symmans, F.16 (AUTHOR), Mondal, S.17 (AUTHOR), Safdar, S.18 (AUTHOR), Herbolsheimer, P.19 (AUTHOR), Boileau, J-F.20 (AUTHOR)
Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS320-S321. 2p.
Database: Academic Search Ultimate
FullText Text:
  Availability: 0
Header DbId: asn
DbLabel: Academic Search Ultimate
An: 189418564
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: 291O DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC).
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Harbeck%2C+N%2E%22">Harbeck, N.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Modi%2C+S%2E%22">Modi, S.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Pusztai%2C+L%2E%22">Pusztai, L.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ohno%2C+S%2E%22">Ohno, S.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wu%2C+J%2E%22">Wu, J.</searchLink><relatesTo>5</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kim%2C+S%2EB%2E%22">Kim, S.B.</searchLink><relatesTo>6</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fabi%2C+A%2E%22">Fabi, A.</searchLink><relatesTo>7</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cao%2C+X%2E%22">Cao, X.</searchLink><relatesTo>8</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Joseph%2C+R%2E%22">Joseph, R.</searchLink><relatesTo>9</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Li%2C+R%2E%22">Li, R.</searchLink><relatesTo>10</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zurawski%2C+B%2E%22">Zurawski, B.</searchLink><relatesTo>11</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Escrivá-de-Romaní%2C+S%2E%22">Escrivá-de-Romaní, S.</searchLink><relatesTo>12</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Chen%2C+S%2EC%2E%22">Chen, S.C.</searchLink><relatesTo>13</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kelly%2C+C%2E%22">Kelly, C.</searchLink><relatesTo>14</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Curigliano%2C+G%2E%22">Curigliano, G.</searchLink><relatesTo>15</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Symmans%2C+F%2E%22">Symmans, F.</searchLink><relatesTo>16</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mondal%2C+S%2E%22">Mondal, S.</searchLink><relatesTo>17</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Safdar%2C+S%2E%22">Safdar, S.</searchLink><relatesTo>18</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Herbolsheimer%2C+P%2E%22">Herbolsheimer, P.</searchLink><relatesTo>19</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Boileau%2C+J-F%2E%22">Boileau, J-F.</searchLink><relatesTo>20</relatesTo> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2025 Supplement 2, Vol. 36, pS320-S321. 2p.
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=189418564
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.annonc.2025.08.720
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 2
        StartPage: S320
    Titles:
      – TitleFull: 291O DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC).
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Harbeck, N.
      – PersonEntity:
          Name:
            NameFull: Modi, S.
      – PersonEntity:
          Name:
            NameFull: Pusztai, L.
      – PersonEntity:
          Name:
            NameFull: Ohno, S.
      – PersonEntity:
          Name:
            NameFull: Wu, J.
      – PersonEntity:
          Name:
            NameFull: Kim, S.B.
      – PersonEntity:
          Name:
            NameFull: Fabi, A.
      – PersonEntity:
          Name:
            NameFull: Cao, X.
      – PersonEntity:
          Name:
            NameFull: Joseph, R.
      – PersonEntity:
          Name:
            NameFull: Li, R.
      – PersonEntity:
          Name:
            NameFull: Zurawski, B.
      – PersonEntity:
          Name:
            NameFull: Escrivá-de-Romaní, S.
      – PersonEntity:
          Name:
            NameFull: Chen, S.C.
      – PersonEntity:
          Name:
            NameFull: Kelly, C.
      – PersonEntity:
          Name:
            NameFull: Curigliano, G.
      – PersonEntity:
          Name:
            NameFull: Symmans, F.
      – PersonEntity:
          Name:
            NameFull: Mondal, S.
      – PersonEntity:
          Name:
            NameFull: Safdar, S.
      – PersonEntity:
          Name:
            NameFull: Herbolsheimer, P.
      – PersonEntity:
          Name:
            NameFull: Boileau, J-F.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 09
              Text: 2025 Supplement 2
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 09237534
          Numbering:
            – Type: volume
              Value: 36
          Titles:
            – TitleFull: Annals of Oncology
              Type: main
ResultId 1